Oruka Therapeutics, Inc.ORKA

$72.34+1.46 (+2.06%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$4B

Mid-cap

+12987%

2017 — today

10-Year Price

-91%

2016 — today

52-Week Range

$10.90$76.39

Current $72.34· 94%

Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.

Valuation in context

P/E ratio

-30.3

N/A

Not meaningful — company is unprofitable

P/B ratio

8.2

Historically pricey

Historically pricey — last 10 years

FCF Yield

-2.3%

Near historic high

Near historic highs — last 10 years

Free · No credit card needed

Get alerted when ORKA is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.